Evidence map›Paper›PMID 29269400›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2018

LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.

Zhiying Yue, Zengjin Yuan, Li Zeng, Ying Wang, Li Lai, Jing Li, Peng Sun, Xiwen Xue, Junyi Qi, Zhengfeng Yang and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Wnt signaling and tumors (Review).Molecular and clinical oncology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Zhiying YueShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Zengjin YuanShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Li ZengShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Ying WangDepartment of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Institute of Biosciences and Technology, Houston, Texas, USA.
Li LaiDepartment of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Institute of Biosciences and Technology, Houston, Texas, USA.
Jing LiEast China Normal University Joint Center for Translational Medicine, Shanghai Fengxian District Central Hospital, Shanghai, China.
Peng SunShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Xiwen XueShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Junyi QiShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Zhengfeng YangShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Yansen ZhengShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Yuanzhang FangLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA.
Dali LiShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Stefan SiwkoDepartment of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Institute of Biosciences and Technology, Houston, Texas, USA.
Yi LiLester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, USA.
Jian LuoShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
Mingyao LiuShanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai, China.
East China Normal University · CNBaylor College of Medicine · USXian Central Hospital · CN

Funding

A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and MetastasisR01CA204926 · NCI · BAYLOR COLLEGE OF MEDICINE · PI LI, YI · 2017 to 2021
$1.8M
NCI NIH HHS R01 CA204926
6 · The paper itself

Abstract

The fourth member of the leucine-rich repeat-containing GPCR family (LGR4, frequently referred to as GPR48) and its cognate ligands, R-spondins (RSPOs) play crucial roles in the development of multiple organs as well as the survival of adult stem cells by activation of canonical Wnt signaling. Wnt/β-catenin signaling acts to regulate breast cancer; however, the molecular mechanisms determining its spatiotemporal regulation are largely unknown. In this study, we identified LGR4 as a master controller of Wnt/β-catenin signaling-mediated breast cancer tumorigenesis, metastasis, and cancer stem cell (CSC) maintenance. LGR4 expression in breast tumors correlated with poor prognosis. Either Lgr4 haploinsufficiency or mammary-specific deletion inhibited mouse mammary tumor virus (MMTV)- PyMT- and MMTV- Wnt1-driven mammary tumorigenesis and metastasis. Moreover, LGR4 down-regulation decreased in vitro migration and in vivo xenograft tumor growth and lung metastasis. Furthermore, Lgr4 deletion in MMTV- Wnt1 tumor cells or knockdown in human breast cancer cells decreased the number of functional CSCs by ∼90%. Canonical Wnt signaling was impaired in LGR4-deficient breast cancer cells, and LGR4 knockdown resulted in increased E-cadherin and decreased expression of N-cadherin and snail transcription factor -2 ( SNAI2) (also called SLUG), implicating LGR4 in regulation of epithelial-mesenchymal transition. Our findings support a crucial role of the Wnt signaling component LGR4 in breast cancer initiation, metastasis, and breast CSCs.-Yue, Z., Yuan, Z., Zeng, L., Wang, Y., Lai, L., Li, J., Sun, P., Xue, X., Qi, J., Yang, Z., Zheng, Y., Fang, Y., Li, D., Siwko, S., Li, Y., Luo, J., Liu, M. LGR4 modulates breast cancer initiation, metastasis, and cancer stem cells.

Indexed as

Gene Expression Regulation, NeoplasticWnt Signaling PathwayAnimalsBreast NeoplasmsCell Line, TumorFemaleHeterograftsMammary Neoplasms, AnimalMiceMice, KnockoutMice, NudeNeoplasm MetastasisNeoplasm ProteinsNeoplasm TransplantationNeoplastic Stem CellsReceptors, G-Protein-CoupledLGR4 protein, humanLGR4 protein, mouseNeoplasm ProteinsReceptors, G-Protein-Coupledepithelial–mesenchymal transitionmammary tumorigenesistumor progressionWnt

Identifiers

PMID29269400
PMCPMC5901378
OpenAlexW2780234406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.